Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Uterine Cervical Neoplasms 1Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphatic Metastasis 1Lung Neoplasms 1Hypoxic Tumours 1Hypoxia 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Surgical Procedures, Operative 7Liver Transplantation 5Lenalidomide 4Blood Specimen Collection 4pomalidomide 3Neoadjuvant Therapy 3Liquid Biopsy 3gilteritinib 2Therapeutics 2Rituximab 2Proteasome Inhibitors 2Observation 2Mohs Surgery 2Mitomycin 2Magnetic Resonance Spectroscopy 2Immunotherapy, Adoptive 2Immunoconjugates 2High-Throughput Nucleotide Sequencing 2Fluorouracil 2Drug Therapy 2DNA, Mitochondrial 2Brentuximab Vedotin 2Bendamustine Hydrochloride 2Antibodies, Monoclonal 2Antibodies, Bispecific 2Amplified Fragment Length Polymorphism Analysis 2trametinib 1romidepsin 1nedaplatin 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Recurrence × fluoroazomycin arabinoside × Clear all
NCT04409314 2023-08-21

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

University of California, San Francisco

Completed
23 enrolled
LymphoidPlasma cell

Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡